Results 141 to 150 of about 5,276 (179)
Some of the next articles are maybe not open access.
Management of MPNST in Neurofibromatosis
2021Malignant peripheral nerve sheath tumours (MPNSTs) are aggressive neoplasms classified as soft tissue sarcomas. Extremely rare in the general population, they are frequently detected in neurofibromatosis type 1 (NF1) patients with a higher incidence, earlier onset and often worse prognosis.
Eric L Zager
exaly +2 more sources
RRM2 as a novel prognostic and therapeutic target of NF1-associated MPNST
Cellular Oncology (Dordrecht), 2023 Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive sarcomas that typically develop in the setting of neurofibromatosis type 1 (NF1) and cause significant morbidity. Conventional therapies are often ineffective for MPNSTs. Ribonucleotide reductase subunit M2 (RRM2) is involved in DNA synthesis and repair, and is overexpressed in multiple ...
Zhichao Wang +2 more
exaly +3 more sources
Oncogenic RABL6A promotes NF1-associated MPNST progression in vivo
Neuro-Oncology Advances, 2022 Abstract Background Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive sarcomas with complex molecular and genetic alterations. Powerful tumor suppressors CDKN2A and TP53 are commonly disrupted along with NF1, a gene that encodes a negative regulator of Ras.
Rebecca Dodd +2 more
exaly +3 more sources
Molecular Cancer Research, 2019
In the July 2019 issue of Molecular Cancer Research , Korfhage and Lombard reviewed the implication of Polycomb repressive complex 2 (PRC2) alterations as drivers of malignant peripheral nerve sheath tumors (MPNST) development ([1][1]).
Wassef, Michel +2 more
openaire +3 more sources
In the July 2019 issue of Molecular Cancer Research , Korfhage and Lombard reviewed the implication of Polycomb repressive complex 2 (PRC2) alterations as drivers of malignant peripheral nerve sheath tumors (MPNST) development ([1][1]).
Wassef, Michel +2 more
openaire +3 more sources
Unmasking Intra-Tumoral Heterogeneity and Clonal Evolution in NF1-MPNST [PDF]
Genes, 2020 Sarcomas are highly aggressive cancers that have a high propensity for metastasis, fail to respond to conventional therapies, and carry a poor 5-year survival rate. This is particularly true for patients with neurofibromatosis type 1 (NF1), in which 8%–13% of affected individuals will develop a malignant peripheral nerve sheath tumor (MPNST).
Patrik Pipkorn +2 more
exaly +4 more sources
Intrasellar malignant peripheral nerve sheath tumor (MPNST)
Acta Neurochirurgica, 2007Intracranial malignant peripheral nerve sheath tumors (MPNST) and intrasellar schwannomas are rare tumors. We describe a case of an intrasellar schwannoma with progression to a MPNST, a finding that, although very rare, extends the differential diagnosis of intrasellar lesions.
Frank Heppner, Y Yonekawa, Yonekawa Y
exaly +4 more sources
A retrospective study of the brachial plexus MPNSTs.
Journal of Clinical Oncology, 2014e21515 Background: Malignant peripheral nerve sheath tumors (MPNSTs) of upper extremity are rare, especially at brachial plexus, and most publications are case reports or with few patients.
Lin Chen +3 more
openaire +1 more source
Overactivation of Ras signaling pathway in CD133+ MPNST cells
Journal of Neuro-Oncology, 2012Cancer stem cells (CSCs) are believed to be the regenerative pool of cells responsible for repopulating tumors. Gaining knowledge about the signaling characteristics of CSCs is important for understanding the biology of tumors and developing novel anti-cancer therapies.
Emma, Borrego-Diaz +11 more
openaire +2 more sources
Relevance of MPNST cell lines as models for NF1 associated-tumors
Journal of Neuro-Oncology, 2013Eric Pasmant +2 more
exaly +3 more sources
Loss of PRC2 Function Promotes MPNST Pathogenesis
Cancer Discovery, 2014Abstract Genetic inactivation of PRC2 components, NF1, and CDKN2A are frequently detected in MPNSTs.
openaire +2 more sources